Panthenol Properties and Uses
Panthenol is used in cosmetics and other consumer products such as pharmaceuticals and biocides. Its wide variety of applications is explained by its properties, most notably the ability to attract and hold moisture and the capacity to enhance skin repair.


Panthenol is an alcohol derivative of vitamin B5, which is also known as Pantothenic Acid. Panthenol and pantothenic acid have the same biological activity and panthenol can be converted by oxidation to vitamin B5 in the skin. Pantothenic acid is found in all living cells and is essential for normal metabolism and hormone production.

In cosmetics and personal care products, panthenol is used as an antistatic, hair conditioning and skin conditioning agent. This ingredient can be used in two forms: D-Panthenol (viscous oil) and DL-Panthenol (crystalline powder). Only D-Panthenol (Dexpanthenol) is biologically active, but both forms have moisturising properties. When used in cosmetics, it is usually present in its D-form or as racemic mixture.

Panthenol is often used in hair conditioners, shampoos, hair sprays, make-up products, skin moisturisers and other products for skin care. On the skin, panthenol can act as a lubricant, giving it a soft and smooth appearance, and also enhance the appearance and feel of hair (e.g., improving its texture). Panthenol is widely used as humectant in cosmetics because of its ability to attract and hold moisture.

The Cosmetic Ingredient Review (CIR) Expert Panel has assessed the safety of Panthenol in cosmetics and concluded it was safe as a cosmetic ingredient when used at the present practices of use and concentration described in the report. According to data received from the 2017 FDA’s Voluntary Cosmetic Registration Program (VCRP), Panthenol was used up to 5.3% in leave-on cosmetics and up to 5% in rinse-off products.

The CIR Panel concluded that panthenol has low potential for systemic toxicity at high doses. This ingredient is not mutagenic in vitro. In several animal and clinical studies, panthenol was non-to-mildly irritant, but it was considered to have minimal potential to cause sensitization and irritation. It was neither photoirritant nor photosensitizer.

When administered in an adequate vehicle (e.g., water-in-oil emulsions), dexpanthenol topically applied has good skin penetration and reaches high local concentrations. Topical applications of these compound are well tolerated, with minimal risk of skin irritancy or sensitization.

The low concentrations of use of panthenol in cosmetics and personal care products and the requirement of vitamin B5 for normal metabolism suggests that the dietary exposure levels to this ingredient would greatly exceed the amount that could be absorbed from cosmetic use.


There are several studies about panthenol (especially dexpanthenol) and its activity on the skin. Creams containing dexpanthenol have shown to significantly accelerate skin barrier repair when compared to placebo. These creams also reduced skin redness (a sign of inflammation, which was induced by sodium lauryl sulfate) and roughness, while enhancing the hydration of the strateum corneum. Dexpanthenol has proven to be able to reduce transepidermal water loss, maintaining skin softness and elasticity. In vitro and in vivo studies show that this compound elicited activation of fibroblast proliferation, which is relevant in wound healing.

The US Food and Drug Administration (FDA) includes panthenol on its list of nutrients and/or dietary supplements Generally Recognized As Safe (GRAS). D-Panthenol is an ingredient approved by the FDA in prescription drug products for use as injectable vitamins. Panthenol is listed as an ingredient that may have chemical activity in wound dressing.

The FDA also includes Panthenol on its list of Over-The-Counter (OTC) drug products that are not generally recognized as safe and effective or are misbranded (“Insect Bite and Sting Drug Products” and “Poison Ivy, Poison Oak, and Poison Sumac Drug Products”).

In the European Union, D-Panthenol is employed in several pharmaceutical presentations (e.g., ointments, nasal sprays), being commonly used in repairing creams. According to the European Chemicals Agency (ECHA), dexpanthenol is used in cosmetics and personal care products, pharmaceuticals, air care products, biocides (e.g., disinfectants, pest control products), polishes and waxes and washing and cleaning products.

If you wish to get more information on panthenol or other related ingredient, do not hesitate to contact us at


  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Cosmetic Ingredient Review (CIR) Expert Panel. Safety Assessment of Panthenol, Pantothenic Acid, and Derivatives as Used in Cosmetics. 2017.
  3. Camargo FB Jr, Gaspar LR, Maia Campos PM. Skin moisturizing effects of panthenol-based formulations. J Cosmet Sci. 2011 Jul-Aug;62(4):361-70.


medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »